Skip to Content
MDPIMDPI

Advanced

Sci. Pharm.Scientia Pharmaceutica
PDF
  • Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
  • Abstract
  • Open Access

16 April 2009

1 Page

Functionality of P-glycoprotein in the Blood-Brain Barrier Mimicking Cell Line PBMEC/C1-2

,
,
,
,
,
,
,
,
…
1
PharmaCon GmbH, Riglergasse 4/5, 1180 Vienna, Austria
2
Department of Medicinal Chemistry, University of Vienna, Althanstraße 14, 1090 Vienna, Austria
3
Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Althanstraße 14, 1090 Vienna, Austria
*
Author to whom correspondence should be addressed.
Sci. Pharm.2009, 77(7), 219;https://doi.org/10.3797/scipharm.oephg.21.PO-20
Version Notes
Order Reprints

Abstract

The blood-brain barrier (BBB) maintains the homeostasis between the central nervous system and the blood circulation [1]. One of the main efflux transporter proteins at the BBB is P-glycoprotein (P-gP) also known as ABCB1 or MDR1. Recently, transport studies with antidepressants suggested presence and functional activity of P-gP in an in vitro model of the BBB based on porcine cell line PBMEC/C1-2 [2]. Due to the important role of P-gP for the transport barrier function of the BBB, the presence and functionability of P-gP was investigated in cell line PBMEC/C1-2 maybe leading to an in vitro BBB model suitable for P-gP substrate screening.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Functionability of NMDA-Receptors in an in vitro model of the Blood-Brain-Barrier
Previous
Transport of NSAIDs across the Blood-Brain Barrier in vitro
Next